💬 [E8624] Fisher's framework argues that patient capital benefits from a time arbitrage advantage, as markets systematically misprice long-term value creation due to short-term focus. He notes that 'every significant price move of any individual common stock occurs because of a changed appraisal by the financial community,' implying corrections create buying opportunities for well-researched growth companies.

💬 [E8626] Fisher's historical case studies reference companies like IBM, Motorola, and Texas Instruments as examples of exceptional growth compounders generating 10-100x returns over decades. His qualitative evaluation framework—emphasizing management depth, sales organization quality, and long-range profit outlook—provides a template for evaluating modern mega-cap technology companies with similar dominant competitive positions.

💬 [E8621] Philip Fisher's classic 1958 framework advocates concentrated portfolios of 5-10 carefully selected stocks, arguing diversification beyond this level represents 'financial incompetence.' He contends superior returns come from deep knowledge of fewer companies rather than broad exposure, with concentration justified by thorough qualitative research and long holding periods spanning decades.

💬 [E8622] Fisher generally favors companies retaining earnings for reinvestment over those paying high dividends, arguing companies with superior reinvestment opportunities compound wealth more effectively than investors receiving dividends. This reflects a growth-over-income allocation philosophy, especially considering tax drag on dividend income and difficulty of finding equivalent reinvestment opportunities.

💬 [E8623] Fisher identifies only three valid reasons for selling growth stocks: (1) recognition of a mistake in original purchase, (2) fundamental deterioration in company characteristics such as management change or market exhaustion, and (3) finding significantly more attractive opportunities. He strongly opposes selling for market timing, profit-taking, or short-term valuation concerns, stating 'the time to sell is—almost never.'

💬 [E8625] Fisher's 15-point framework emphasizes R&D effectiveness relative to company size as a core evaluation criterion, with research-driven companies creating new product categories or improving cost structures identified as key catalysts. This framework for evaluating technology reinvestment cycles maps onto modern AI capex analysis, particularly regarding management's ability to reinvest capital at high returns while maintaining competitive advantages.